gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Interferon, alpha 2

Interferon-alpha, interferon alpha-2b
This gene is a member of the alpha interferon gene cluster on chromosome 9. The encoded protein is a cytokine produced in response to viral infection. Use of the recombinant form of this protein has been shown to be effective in reducing the symptoms and duration of the common cold. [provided by RefSeq, Jun 2011] (from NCBI)
Top mentioned proteins: HAD, CAN, AGE, ACID, iMpact
Papers on Interferon-alpha
Ocular Surface Squamous Neoplasia in a Living-Related Conjunctival Limbal Allograft.
Holland et al., Cincinnati, United States. In Cornea, Feb 2016
Incisional biopsy was performed, and topical interferon alpha-2b was initiated.
Phase 2 Randomized Controlled Trial of Radiation Therapy Plus Concurrent Interferon-Alpha and Retinoic Acid Versus Cisplatin for Stage III Cervical Carcinoma.
Miller et al., Lyon, France. In Int J Radiat Oncol Biol Phys, Feb 2016
PURPOSE: Because a combination of retinoic acid, interferon-alpha, and radiation therapy demonstrated synergistic action and effectiveness to treat advanced cervical cancers in earlier studies, we designed this randomized phase 2 open-label trial to assess efficacy and safety of interferon alpha-2b (IFN) and 13-cis-retinoic acid (RA) administered concomitantly with radiation therapy (IFN-RA-radiation) to treat stage III cervical cancer.
Interferon-alpha-induced inflammation is associated with reduced glucocorticoid negative feedback sensitivity and depression in patients with hepatitis C virus.
Miller et al., Atlanta, United States. In Physiol Behav, Jan 2016
UNASSIGNED: Major medical illnesses are associated with increased risk for depression and alterations in hypothalamic-pituitary-adrenal (HPA) axis function.
Interferon-α acutely impairs whole-brain functional connectivity network architecture - A preliminary study.
Harrison et al., Milano, Italy. In Brain Behav Immun, Jan 2016
UNASSIGNED: Interferon-alpha (IFN-α) is a key mediator of antiviral immune responses used to treat Hepatitis C infection.
Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone.
Cassinat et al., Paris, France. In Leukemia, Dec 2015
UNASSIGNED: Interferon alpha (IFN-α) has been used for over 30 years to treat myeloproliferative neoplasms (MPNs).
[Adjuvant therapy and interdisciplinary follow-up care of conjunctival melanoma].
Cursiefen et al., Köln, Germany. In Ophthalmologe, Nov 2015
Novel adjuvant approaches include topical interferon alpha-2b immunotherapy, topical vascular endothelial growth factor (VEGF) inhibitors or in cases of BRAF mutations personalized therapy using selective BRAF inhibitors or in combination with mitogen-activated protein kinase (MAPK) and extracellular signal-regulated kinase (ERK), MAPK/ERK (MEK) inhibitors.
[Antitumor effect of mIFN-λ3 in C57BL/6 mice model for papilloma tumors].
Razavinikoo et al., Tehrān, Iran. In Mol Biol (mosk), Sep 2015
Interferon-alpha (IFN-α) immunotherapy is one of the promising methods for tumor treatment, although numerous side effects were observed in clinical trials.
Mutations of the human interferon alpha-2b gene in brain tumor patients exposed to different environmental conditions.
Sheikh et al., Lahore, Pakistan. In Cancer Gene Ther, May 2015
This study was aimed at finding out mutations of an anticancerous, antiviral and immunomodulatory gene (human interferon alpha-2b) in low- and high-grade brain tumor patients and correlate from hematological profiles.
Interventions for dialysis patients with hepatitis C virus (HCV) infection.
Suvarna et al., India. In Cochrane Database Syst Rev, 2014
Subgroup analysis comparing high and low doses of PEG interferon alpha-2a (135 µg/week versus 90 µg/week) and PEG interferon alpha-2b (1 µg/kg versus 0.5 µg/kg body weight/week) found no significant difference in mortality (2 studies (97 participants): RR 4.30, 95% CI 0.76 to 24.33), relapses (1 study (81 participants): RR 1.11, 95% CI 0.45 to 2.77), end of treatment response (2 studies (97 participants): RR 1.42, 95% CI 0.51 to 3.90), sustained virological response (2 studies (97 participants): RR 1.19, 95% CI 0.68 to 2.07), treatment discontinuation (2 studies (97 participants): RR 1.20, 95% CI 0.63 to 2.28), patients with adverse events (2 studies (97 participants): RR 1.05, 95% CI 0.61 to 1.83) or serious adverse events (2 studies (97 participants): RR 1.24, 95% CI 0.72 to 2.14).
ISG15 as a novel prognostic biomarker for hepatitis B virus-related hepatocellular carcinoma.
Zuo et al., Changsha, China. In Int J Clin Exp Med, 2014
Interferon-alpha (IFN-α) has recently been recognized to harbor therapeutic potential in prevention and treatment of HCC.
USP18 establishes the transcriptional and anti-proliferative interferon α/β differential.
Pellegrini et al., Paris, France. In Biochem J, 2012
interferon-stimulated genes which exerts its negative feedback action by taking advantage of the weakness of IFNalpha2 binding to the receptor
Reduced interferon (IFN)-α conditioned by IFNA2 (-173) and IFNA8 (-884) haplotypes is associated with enhanced susceptibility to severe malarial anemia and longitudinal all-cause mortality.
Perkins et al., Albuquerque, United States. In Hum Genet, 2012
variation at IFNA2 -173 and IFNA8 -884 conditions reduced IFN-alpha production, and increased susceptibility to SMA and mortality
Spontaneous mutation of the Dock2 gene in Irf5-/- mice complicates interpretation of type I interferon production and antibody responses.
Bhattacharya et al., Saint Louis, United States. In Proc Natl Acad Sci U S A, 2012
A spontaneous genomic duplication and frameshift mutation in the guanine exchange factor dedicator of cytokinesis 2 (Dock2) that has arisen in at least a subset of circulating Irf5(-/-) mice and inadvertently been bred to homozygosity.
[Construction and expression of the efficient recombinant plasmid pEE14.1-IFN-α expressing human IFN-α].
Yan et al., Qufu, China. In Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2012
Data indicate that the production of IFN-alpha in supernatant of transfected cells was about 3.15 ng/mL.
siRNA high-throughput kinase library screen identifies protein kinase, DNA-activated catalytic polypeptide to play a role in MyD88-induced IFNA2 activation and IL-8 secretion.
Morley et al., Stevenage, United Kingdom. In Biotechnol Appl Biochem, 2012
protein kinase, DNA-activated catalytic polypeptide (PRKDC), was confirmed to play a role in MyD88-induced IFNA2 activation and IL-8 secretion
Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b.
Ajani et al., Houston, United States. In J Clin Oncol, 2008
The combination of bevacizumab (BEV) and pegylated (PEG) interferon alpha-2b was evaluated among patients with metastatic or unresectable carcinoid tumors.
Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6.
Akira et al., Suita, Japan. In Nat Immunol, 2004
A subset of TLRs, TLR7, TLR8 and TLR9, induces antiviral responses by producing interferon-alpha (IFN-alpha).
Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial.
Italian Melanoma Intergroup et al., Forlì, Italy. In J Clin Oncol, 2002
PURPOSE: Phase II and III studies have shown that the addition of interleukin-2 (IL-2) and interferon alpha-2b (IFN alpha-2b) in multiagent chemotherapy (CT) for advanced melanoma increases overall response (OR), albeit without clear evidence of an improvement in overall survival (OS).
Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data.
Weeks et al., Charlottesville, United States. In J Clin Oncol, 2002
PURPOSE: High-dose adjuvant interferon alpha-2b (IFN alpha 2b) for high-risk melanoma is a 1-year regimen that improves relapse-free and overall survival but has significant toxicity.
Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer.
Logothetis et al., Houston, United States. In J Clin Oncol, 2002
PURPOSE: Previously, we developed a novel biochemotherapy regimen combining interferon alpha-2b with fluorouracil and cisplatin (FAP).
share on facebooktweetadd +1mail to friends